Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

6.6K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
6.6K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

8.3K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
8.3K
Separation of Sister Chromatids02:17

Separation of Sister Chromatids

4.7K
At the transition from prophase to metaphase, there is a reduction in cohesion along the chromosomal arms, resulting in the resolution of sister chromatids. However, residual cohesin connections remain to hold the sister chromatids together until the transition from metaphase to anaphase. The residual connection prevents any premature separation of sister chromatids, blocking the risks of aneuploidy within the daughter cells.
At the onset of anaphase, separase, a proteolytic enzyme, is...
4.7K
Separation of Sister Chromatids02:17

Separation of Sister Chromatids

2.6K
2.6K
Base-pairing and DNA Repair02:27

Base-pairing and DNA Repair

94.4K
94.4K
Nucleotide Excision Repair01:08

Nucleotide Excision Repair

13.9K
13.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Results of a randomized, placebo-controlled, first-in-human trial of topical CY-002 in patients with cutaneous warts.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Using machine learning techniques to characterize sleep-deprived driving behavior.

Traffic injury prevention·2021
Same author

Towards remote monitoring in pediatric care and clinical trials-Tolerability, repeatability and reference values of candidate digital endpoints derived from physical activity, heart rate and sleep in healthy children.

PloS one·2021
Same author

The use of machine learning improves the assessment of drug-induced driving behaviour.

Accident; analysis and prevention·2020
Same author

Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation.

Pharmacological reviews·2020
Same journal

N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

British journal of clinical pharmacology·2026
Same journal

Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

British journal of clinical pharmacology·2026
Same journal

Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

British journal of clinical pharmacology·2026
Same journal

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

British journal of clinical pharmacology·2026
Same journal

Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

British journal of clinical pharmacology·2026
Same journal

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: Apr 4, 2026

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

40.2K

Olaparib.

S C Goulooze1, A F Cohen1,2, R Rissmann1,2

  • 1Centre for Human Drug Research, Leiden, the Netherlands.

British Journal of Clinical Pharmacology
|September 8, 2015
PubMed
Summary
This summary is machine-generated.

Olaparib treats BRCA-associated ovarian cancer by inhibiting poly(ADP-ribose) polymerase. This blocks DNA repair, causing synthetic lethality in cancer cells with homologous recombination defects.

More Related Videos

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.9K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.7K

Related Experiment Videos

Last Updated: Apr 4, 2026

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

40.2K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.9K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Olaparib is a targeted therapy for specific cancers.
  • BRCA-associated cancers have impaired DNA repair mechanisms.
  • Platinum-sensitive ovarian cancer is a key indication.

Purpose of the Study:

  • To explain the mechanism of action of Olaparib.
  • To highlight its efficacy in BRCA-associated cancers.
  • To detail the concept of synthetic lethality in cancer treatment.

Main Methods:

  • Inhibition of poly(ADP-ribose) polymerase (PARP) by Olaparib.
  • Exploitation of homologous recombination pathway defects.
  • Induction of synthetic lethality in cancer cells.

Main Results:

  • Olaparib effectively blocks single-strand DNA break repair.
  • This leads to accumulation of DNA damage in cancer cells.
  • Synthetic lethality is achieved in BRCA-mutated cancer cells.

Conclusions:

  • Olaparib is a potent PARP inhibitor.
  • Its mechanism relies on synthetic lethality in BRCA-deficient cancers.
  • Olaparib offers a targeted treatment strategy for ovarian cancer.